(1S,5S)-N-ethyl-6-(4-fluorophenyl)-9,9-dimethyl-3,6-diazabicyclo[3.2.2]nonane-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1S,5S)-N-ethyl-6-(4-fluorophenyl)-9,9-dimethyl-3,6-diazabicyclo[3.2.2]nonane-3-carboxamide
• 化学式: C₁₈H₂₆FN₃O
• 分子量: 319.422
• InChiKey: VDPREPHUSUHYTL-CZUORRHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (1R,5S)-6-(4-fluorophenyl)-9,9-dimethyl-3,6-diazabicyclo[3.2.2]nonane 、 异氰酸乙酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以80%的产率得到(1S,5S)-N-ethyl-6-(4-fluorophenyl)-9,9-dimethyl-3,6-diazabicyclo[3.2.2]nonane-3-carboxamide
  参考文献：
  名称：

  [EN] LYSYL OXIDASE INHIBITORS
  [FR] INHIBITEURS DE LA LYSYLE OXYDASE

  摘要：

  这项发明涉及作为赖氨酸氧化酶（LOX）和赖氨酸氧化酶类（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）抑制剂有用的化合物。此外，还考虑了包括这些化合物的药物组合物以及利用这些化合物治疗由LOX和LOXL介导的疾病，例如癌症。特别是像目前的这些化合物这样的LOX抑制剂可能用于治疗与EGFR相关的癌症。本发明还考虑了预测对LOX抑制剂响应性的生物标志物的鉴定。

  公开号：

  WO2019073251A1

文献信息

• Lysyl oxidase inhibitors
  申请人：The Institute of Cancer Research: Royal Cancer Hospital

  公开号：US11325915B2

  公开（公告）日：2022-05-10

  This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.

  本发明涉及可用作赖氨酰氧化酶（LOX）和赖氨酰氧化酶样（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）抑制剂的化合物。此外，还考虑了包含这些化合物的药物组合物以及这些化合物在治疗由 LOX 和 LOXL 介导的疾病（例如癌症）中的用途。特别是LOX抑制剂，如本发明化合物，可用于治疗与表皮生长因子受体相关的癌症。本发明还考虑鉴定预测对 LOX 抑制剂反应性的生物标志物。
• LYSYL OXIDASE INHIBITORS
  申请人：The Institute of Cancer Research: Royal Cancer Hospital

  公开号：US20200331922A1

  公开（公告）日：2020-10-22

  This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
• [EN] LYSYL OXIDASE INHIBITORS<br/>[FR] INHIBITEURS DE LA LYSYLE OXYDASE
  申请人：THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL

  公开号：WO2019073251A1

  公开（公告）日：2019-04-18

  This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.

  这项发明涉及作为赖氨酸氧化酶（LOX）和赖氨酸氧化酶类（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）抑制剂有用的化合物。此外，还考虑了包括这些化合物的药物组合物以及利用这些化合物治疗由LOX和LOXL介导的疾病，例如癌症。特别是像目前的这些化合物这样的LOX抑制剂可能用于治疗与EGFR相关的癌症。本发明还考虑了预测对LOX抑制剂响应性的生物标志物的鉴定。